Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities

被引：2
|
作者：
Ma, Christopher [1 ]
Choi, May Y. [1 ]
机构：
[1] Mayo Clin, Dept Gastroenterol & Hepatol, Phoenix, AZ 85054 USA
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2022年 / 7卷 / 02期
关键词：
MAINTENANCE THERAPY; INDUCTION;
D O I：
10.1016/S2468-1253(21)00432-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：110 / 112
页数：3
相关论文
共 50 条
  • [31] Current new challenges in the management of ulcerative colitis
    Fukuda, Tomohiro
    Naganuma, Makoto
    Kanai, Takanori
    INTESTINAL RESEARCH, 2019, 17 (01) : 36 - 44
  • [32] Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
    Sandborn, William J.
    Danese, Silvio
    Leszczyszyn, Jaroslaw
    Romatowski, Jacek
    Altintas, Engin
    Peeva, Elena
    Hassan-Zahraee, Mina
    Vincent, Michael S.
    Reddy, Padmalatha S.
    Banfield, Christopher
    Salganik, Mikhail
    Banerjee, Anindita
    Gale, Jeremy D.
    Hung, Kenneth E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (10) : 2616 - 2628
  • [33] Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
    D'Amico, Ferdinando
    Magro, Fernando
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (05) : 835 - 844
  • [34] Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions
    Holvoet, Tom
    Lobaton, Triana
    Hindryckx, Pieter
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2021, 14 : 71 - 81
  • [35] Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis
    Yoon, Hyuk
    INTESTINAL RESEARCH, 2019, 17 (03) : 283 - 284
  • [36] Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn's Disease and Ulcerative Colitis
    Niu, Chengu
    Zhang, Jing
    Napel, Mahesh
    Boppana, Leela Krishna Teja
    Anas, Hashem
    Jadhav, Nagesh
    Dunnigan, Karin
    Okolo, Patrick I.
    CLINICAL DRUG INVESTIGATION, 2024, 44 (06) : 371 - 385
  • [37] Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study
    Croft, Nicholas M.
    Faubion, William A., Jr.
    Kugathasan, Subra
    Kierkus, Jaroslaw
    Ruemmele, Frank M.
    Shimizu, Toshiaki
    Mostafa, Nael M.
    Venetucci, Mary
    Finney-Hayward, Tricia
    Gonzalez, Yuri Sanchez
    Bereswill, Mareike
    Lazar, Andreas
    Turner, Dan
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (08): : 616 - 627
  • [38] Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
    Matsuoka, Katsuyoshi
    Hisamatsu, Tadakazu
    Mikami, Yohei
    Yamamoto, Takayuki
    Motoya, Satoshi
    Shinzaki, Shinichiro
    Iwakiri, Ryuichi
    Sugiura, Kenkichi
    Nishimura, Kunihiko
    Kajita, Mika
    Fernandez, Jovelle L.
    ADVANCES IN THERAPY, 2023, 40 (06) : 2902 - 2914
  • [39] Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Essat, Munira
    Tappenden, Paul
    Ren, Shijie
    Bessey, Alice
    Archer, Rachel
    Wong, Ruth
    Lobo, Alan
    Hoque, Sami
    PHARMACOECONOMICS, 2016, 34 (03) : 245 - 257
  • [40] Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan
    Kobayashi, Taku
    Hoshi, Masato
    Yuasa, Akira
    Arai, Shoko
    Ikeda, Mitsunobu
    Matsuda, Hiroyuki
    Kim, Seok-Won
    Hibi, Toshifumi
    PHARMACOECONOMICS, 2023, 41 (05) : 589 - 604
12345